Compton Anthony
Saint Joseph's Hospital of Atlanta, Georgia 30342, USA.
Pharmacotherapy. 2002 Jun;22(6 Pt 2):119S-127S. doi: 10.1592/phco.22.10.119s.33615.
Despite advances in percutaneous coronary intervention (PCI) techniques and adjunctive therapies, the risks of ischemic and bleeding complications with PCI remain significant. These complications are associated with significant morbidity and mortality, as well as substantially higher costs. Bivalirudin is the only antithrombotic agent that has been shown to reduce both ischemic and hemorrhagic complications associated with PCI. Cost models drawn from the results of three clinical trials of bivalirudin have estimated its potential impact on total medical costs. In addition, the number needed to treat to avoid a bleeding complication has been calculated based on patients shown to have a heightened risk of bleeding in the Bivalirudin Angioplasty Trial. In all models assessed, the use of bivalirudin offset most of its own cost through reductions in bleeding and ischemic complications.
尽管经皮冠状动脉介入治疗（PCI）技术及辅助治疗取得了进展，但PCI相关的缺血和出血并发症风险仍然很高。这些并发症与显著的发病率和死亡率相关，且成本也大幅增加。比伐芦定是唯一已被证明可降低与PCI相关的缺血和出血并发症的抗血栓药物。根据比伐芦定三项临床试验结果得出的成本模型估算了其对总医疗成本的潜在影响。此外，根据比伐芦定血管成形术试验中显示出血风险增加的患者计算出了避免出血并发症所需的治疗人数。在所有评估的模型中，使用比伐芦定通过减少出血和缺血并发症抵消了其大部分自身成本。
